Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Lendify in connection with new financing and redemption of bonds
Mandate

Vinge advised Lendify in connection with new financing and redemption of bonds

February 12, 2019 Banking and Finance

Lendify AB (“Lendify”), an online lender and one of Sweden’s most notable challengers in the banking sector, has secured new financing of up to SEK 1.000.000.000 from a large Swedish institution for the purpose of further financing its lending operations.

In connection with the new financing, Lendify’s two wholly owned subsidiaries, Lendify Sweden 1 AB and Lendify Sweden 2 AB, redeemed and de-listed their outstanding bonds from the Debt Securities list at the Nordic Derivatives Exchange.

Together with the management of the company, the institutional investor, the arranger and their legal advisors, Vinge has acted for Lendify in the structuring, documenting and execution of the transaction.

Vinge’s team mainly consisted of partner Albert Wållgren, associates Sebastian Frisk, Lionardo Ojeda and Axel Jansson (Banking and Finance) and partner Emma Stuart-Beck and associates Malin Haag and Caroline Krassén (Financial Services).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026